Skip to main content
KIDS
NASDAQ Industrial Applications And Services

OrthoPediatrics Q2 Revenue Jumps 15% to $70.5M, Losses Steady; New $20M Credit Line Secured

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$21.62
Mkt Cap
$555.31M
52W Low
$14.42
52W High
$22.795
52W Position info
50% above low
Off High info
5.2% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

KIDS sits 50% above its 52-week low of $14.42.

Summary

OrthoPediatrics posted Q2 2026 revenue of $70.5 million, a 15% year-over-year increase, alongside a net loss of $7.2 million. The company also unveiled a new $20 million credit facility and a post-quarter acquisition in the UK.


Key Events · Earnings and Guidance · KIDS

  • Q2 Revenue Up 15%

    Net revenue reached $70.5 million, driven by a 26% surge in trauma and deformity sales to $52.6 million. Scoliosis revenue dipped 9% to $16.9 million.

  • Losses Flat Despite Growth

    Net loss was $7.2 million, nearly unchanged from $7.1 million a year ago, as higher interest expense offset improved gross margins (74% vs 72%).

  • New $20M Credit Line Secured

    On March 31, 2026, the company amended its term loan to add a $20 million delayed-draw facility, undrawn as of June 30, 2026, with interest at SOFR + 6.50%.

  • Liquidity Position

    Cash, restricted cash, and short-term investments totaled $47.9 million at quarter-end. Management expects this plus operating cash flows to fund operations for at least 12 months.


Analysis · KIDS · Industrial Applications And Services

A 15% jump in revenue to $70.5 million underscores OrthoPediatrics' momentum, fueled by trauma and deformity products. While net losses held steady at $7.2 million, the company fortified its financial flexibility with a new $20 million delayed-draw term loan, avoiding immediate dilution. The balance sheet carries $47.9 million in cash and investments, and management reaffirmed that existing resources can fund operations for at least the next twelve months. A subsequent bolt-on acquisition of a UK spinal device maker further signals intent to broaden the scoliosis portfolio.

At the time of this filing, KIDS was trading at $21.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $555.3M. The 52-week trading range was $14.42 to $22.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KIDS - Latest Insights

KIDS
Aug 04, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.88
Real-time Price: $21.55 info
Change: +$0.665 (+3%) info
Market Cap: $553.383M info
KIDS
Aug 04, 2026, 4:28 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.88
Real-time Price: $21.55 info
Change: +$0.665 (+3%) info
Market Cap: $553.383M info
KIDS
Aug 04, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.88
Real-time Price: $21.55 info
Change: +$0.665 (+3%) info
Market Cap: $553.383M info
KIDS
Jun 24, 2026, 7:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.58
Real-time Price: $21.55 info
Change: +$2.97 (+16%) info
Market Cap: $553.383M info
KIDS
Jun 04, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.10
Real-time Price: $21.55 info
Change: +$3.45 (+19%) info
Market Cap: $553.383M info